Gaurav Gulati1, Robin Ruthazer2, David Denofrio3, Amanda R Vest3, David Kent4, Michael S Kiernan3. 1. Cardiovascular Center, Tufts Medical Center; Predictive Analytics and Comparative Effectiveness Center. Electronic address: ggulati@tuftsmedicalcenter.org. 2. Clinical and Translational Sciences Institute, Tufts Medical Center, Boston, Massachusetts. 3. Cardiovascular Center, Tufts Medical Center. 4. Predictive Analytics and Comparative Effectiveness Center.
Abstract
BACKGROUND: Elevated pulmonary vascular resistance (PVR) is common in patients with advanced heart failure. PVR generally improves after left ventricular assist device (LVAD) implantation, but the rate of decrease has not been quantified and the patient characteristics most strongly associated with this improvement are unknown. METHODS AND RESULTS: We analyzed 1581 patients from the Interagency Registry for Mechanically Assisted Circulatory Support registry who received a primary continuous-flow LVAD, had a baseline PVR of ≥3 Wood units (WU), and had PVR measured at least once postoperatively. Multivariable linear mixed effects modeling was used to evaluate independent associations between postoperative PVR and patient characteristics. PVR decreased by 1.53 WU (95% confidence interval [CI] 1.27-1.79 WU) per month in the first 3 months postoperatively, and by 0.066 WU (95% CI 0.060-0.070 WU) per month thereafter. Severe mitral regurgitation at any time during follow-up was associated with a 1.29 WU (95% CI 1.05-1.52 WU) higher PVR relative to absence of mitral regurgitation at that time. In a cross-sectional analysis, 15%-25% of patients had persistently elevated PVR of ≥3 WU at any given time within 36 months after LVAD implantation. CONCLUSION: The PVR tends to decrease rapidly early after implantation, and only more gradually thereafter. Residual mitral regurgitation may be an important contributor to elevated postoperative PVR. Future research is needed to understand the implications of elevated PVR after LVAD implantation and the optimal strategies for prevention and treatment.
BACKGROUND: Elevated pulmonary vascular resistance (PVR) is common in patients with advanced heart failure. PVR generally improves after left ventricular assist device (LVAD) implantation, but the rate of decrease has not been quantified and the patient characteristics most strongly associated with this improvement are unknown. METHODS AND RESULTS: We analyzed 1581 patients from the Interagency Registry for Mechanically Assisted Circulatory Support registry who received a primary continuous-flow LVAD, had a baseline PVR of ≥3 Wood units (WU), and had PVR measured at least once postoperatively. Multivariable linear mixed effects modeling was used to evaluate independent associations between postoperative PVR and patient characteristics. PVR decreased by 1.53 WU (95% confidence interval [CI] 1.27-1.79 WU) per month in the first 3 months postoperatively, and by 0.066 WU (95% CI 0.060-0.070 WU) per month thereafter. Severe mitral regurgitation at any time during follow-up was associated with a 1.29 WU (95% CI 1.05-1.52 WU) higher PVR relative to absence of mitral regurgitation at that time. In a cross-sectional analysis, 15%-25% of patients had persistently elevated PVR of ≥3 WU at any given time within 36 months after LVAD implantation. CONCLUSION: The PVR tends to decrease rapidly early after implantation, and only more gradually thereafter. Residual mitral regurgitation may be an important contributor to elevated postoperative PVR. Future research is needed to understand the implications of elevated PVR after LVAD implantation and the optimal strategies for prevention and treatment.
Authors: Mandeep R Mehra; Charles E Canter; Margaret M Hannan; Marc J Semigran; Patricia A Uber; David A Baran; Lara Danziger-Isakov; James K Kirklin; Richard Kirk; Sudhir S Kushwaha; Lars H Lund; Luciano Potena; Heather J Ross; David O Taylor; Erik A M Verschuuren; Andreas Zuckermann Journal: J Heart Lung Transplant Date: 2016-01 Impact factor: 10.247
Authors: Francesca Bursi; Sheila M McNallan; Margaret M Redfield; Vuyisile T Nkomo; Carolyn S P Lam; Susan A Weston; Ruoxiang Jiang; Véronique L Roger Journal: J Am Coll Cardiol Date: 2012-01-17 Impact factor: 24.094
Authors: Ryan J Tedford; Paul M Hassoun; Stephen C Mathai; Reda E Girgis; Stuart D Russell; David R Thiemann; Oscar H Cingolani; James O Mudd; Barry A Borlaug; Margaret M Redfield; David J Lederer; David A Kass Journal: Circulation Date: 2011-11-30 Impact factor: 29.690
Authors: Elisa Mikus; Alexander Stepanenko; Thomas Krabatsch; Antonio Loforte; Michael Dandel; Hans Brendan Lehmkuhl; Roland Hetzer; Evgenij V Potapov Journal: Eur J Cardiothorac Surg Date: 2011-02-26 Impact factor: 4.191
Authors: Robert L Kormos; Jeffrey J Teuteberg; Francis D Pagani; Stuart D Russell; Ranjit John; Leslie W Miller; Todd Massey; Carmelo A Milano; Nader Moazami; Kartik S Sundareswaran; David J Farrar Journal: J Thorac Cardiovasc Surg Date: 2010-02-04 Impact factor: 5.209
Authors: Daniel H Enter; Anthony Zaki; Brett F Duncan; Jane Kruse; Adin-Cristian Andrei; Zhi Li; S Chris Malaisrie; Sanjiv J Shah; James D Thomas; Patrick M McCarthy Journal: J Thorac Cardiovasc Surg Date: 2016-01-22 Impact factor: 5.209
Authors: Avishay Grupper; Israel Mazin; Kobi Faierstein; Adam Kurnick; Elad Maor; Dan Elian; Israel M Barbash; Victor Guetta; Ehud Regev; Avi Morgan; Amit Segev; Jacob Lavee; Paul Fefer Journal: Front Cardiovasc Med Date: 2022-04-26
Authors: Paolo Manca; Vincenzo Nuzzi; Antonio Cannatà; Matteo Castrichini; Daniel I Bromage; Antonio De Luca; Davide Stolfo; Uwe Schulz; Marco Merlo; Gianfranco Sinagra Journal: Heart Fail Rev Date: 2022-03-22 Impact factor: 4.654